Investor Relations
Nov 09, 2018
OPKO Health Reports Third Quarter 2018 Financial Results MORE >>
Nov 08, 2018
BioReference Laboratories Named as Preferred Laboratory with Horizon Healthcare Services MORE >>
Nov 08, 2018
OPKO Health to Announce Third Quarter 2018 Financial Results on November 9, 2018 MORE >>
Sep 14, 2018
OPKO Confirms Resumption of Common Stock Trading on Nasdaq MORE >>

Press Releases

All Releases
OPKO Health to Host Analyst & Investor Day in New York City on June 15
Jun 14, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) (" OPKO " or the "Company") announces that it will host an Analyst & Investor Day on Wednesday, June 15, 2016 beginning at 4:30 p.m. local time in New York City . Phillip Frost , M.D., Chairman and Chief Executive Officer of OPKO Health , will
OPKO Health Announces Move to NASDAQ Stock Market
Jun 13, 2016
Ticker Symbol to Remain OPK, Trading to Begin June 24 MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) (" OPKO " or the "Company") announces that it will move its stock exchange listing to The NASDAQ Stock Market from The New York Stock Exchange (the "NYSE").
OPKO to Discuss Draft Coverage Determinations for 4Kscore® Test at 2016 Jefferies Healthcare Conference
Jun 07, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) today announced that senior management will discuss recent draft local coverage determinations by certain Medicare Administrative Contractors for OPKO's 4Kscore® test at the Jefferies Healthcare Conference in New York City on Thursday, June
OPKO Health to Present at the 2016 Jefferies Healthcare Conference
Jun 02, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT) . The presentation will be webcast on the OPKO Investor Relations page of the corporate
OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination for 4Kscore® Test
May 27, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company") announces that Novitas Solutions has issued a draft local coverage determination for the 4Kscore ® Test, the only blood test that accurately identifies an individual patient's risk for high-grade, aggressive prostate
OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs
May 11, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK ) today announced the appointment of Douglass Laidlaw , PhD as Vice President of Medical Affairs to support the anticipated launch of RAYALDEE ® . Dr. Laidlaw has over 15 years of experience in leading strategic planning, development and
OPKO Announces Appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access
May 10, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK ) today announced the appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access to support the anticipated launch of RAYALDEE ® . Mr. Nusbickel has over 25 years of pharmaceutical experience with
OPKO Health Reports First Quarter Financial and Operating Results
May 09, 2016
Consolidated Revenue Increased to $291.0 Million From $30.1 Million for the First Quarter of 2016 as compared to the 2015 period Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and OPKO Health Entered into Agreement for OPKO's RAYALDEE® ; OPKO to Receive up to $282 Million in Upfront and
Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO's RAYALDEE®
May 09, 2016
Vifor Fresenius Medical Care Renal Pharma obtains rights to commercialize RAYALDEE ® in Europe , Canada and certain other international markets OPKO to receive up to USD 282 million in upfront and milestone payments, plus tiered double-digit royalties OPKO and Vifor Fresenius Medical Care Renal
OPKO to Announce First Quarter Operating and Financial Results on May 9, 2016
Apr 28, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK), a multinational biopharmaceutical and diagnostics company, will release operating and financial results for the three months ended March 31, 2016 , after the close of the U.S. financial markets on Monday, May 9, 2016 .
OPKO Presents Additional Data on RAYALDEE® at National Kidney Foundation Spring Clinical Meetings 2016
Apr 28, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) , announced that additional data on RAYALDEE as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at the National Kidney Foundation Spring Clinical Meetings, underway in Boston, MA.
FDA Accepts Resubmission of New Drug Application for RAYALDEE®
Apr 27, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK ) today announced the U.S. Food and Drug Administration (FDA) has accepted OPKO's resubmission on April 22, 2016 of the New Drug Application (NDA) for RAYALDEE ® (calcifediol) for the treatment of secondary hyperparathyroidism (SHPT) in
OPKO Announces Appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales
Apr 25, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK ) today announced the appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales to support the anticipated launch of RAYALDEE ® . Mr. DeMarco has over 30 years of commercial pharmaceutical experience with established large
OPKO Presents Additional Data on RAYALDEE® at ENDO 2016
Apr 01, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) , announced that additional data on RAYALDEE as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at the Endocrine Society's 98 th Annual Meeting, underway in Boston, MA.
OPKO Presents Additional Data on RAYALDEE® to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease
Mar 31, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) , announced that additional data on RAYALDEE as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at the Vitamin D Workshop , underway in Boston, MA.
OPKO Receives Complete Response Letter from FDA for RAYALDEE® New Drug Application
Mar 30, 2016
Sole issue relates to third-party manufacturing observations No new clinical studies requested No safety or efficacy issues identified Management to host conference call today at 8:30 a.m. Eastern time MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) announces that the U.S.
OPKO Health Announces Executive Appointment
Mar 28, 2016
Ronald Trust , Ph.D., MBA, Appointed Vice President of Regulatory Affairs MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK ) today announced the appointment of Dr. Ronald Trust as Vice President of Regulatory Affairs of OPKO Pharmaceuticals . Prior to joining OPKO, Ron held senior
OPKO To Present 18-24 Month Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) from Open Label Extension (OLE) Phase 2 Pediatric Growth Hormone Deficiency Clinical Study in Oral Presentation at ENDO 2016
Mar 24, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced it will present 18-24 month clinical data from its ongoing open label extension study for hGH-CTP in an oral presentation at the Endocrine Society's 98 th Annual Meeting to be held April 1-4, 2016 , in Boston, MA.
OPKO Health Announces Dosing of First Subject in Phase 1 Clinical Study of a Long-Acting Oxyntomodulin for the Treatment of Obesity and Type II Diabetes
Mar 16, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced dosing of the first subject in a Phase 1 single dose escalation study evaluating the safety and pharmacokinetics of a long-acting Oxyntomodulin (MOD-6031) in healthy, overweight or obese subjects.
OPKO 4Kscore® Recommended in 2016 European Association of Urology Prostate Cancer Guidelines
Mar 15, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the decision of the European Association of Urology (EAU) Prostate Cancer Guidelines Panel to include the 4Kscore® Test in the 2016 EAU Guidelines for Prostate Cancer. The panel concluded that the 4Kscore, as a blood test with
Displaying 81 - 100 of 366